english.prescrire.org > Spotlight > 100 most recent > Ritlecitinib (Litfulo°) in severe alopecia areata in adults and adolescents

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Ritlecitinib (Litfulo°) in severe alopecia areata in adults and adolescents

 Marketing Authorisations  Ritlecitinib is an immunosuppressant that inhibits various kinases, including Janus kinases. It has been authorised in the European Union for the treatment of adults and adolescents with severe alopecia areata.
Full article available for download by subscribers

 ©Prescrire 1 March 2025

Source: "Ritlecitinib (Litfulo°) in severe alopecia areata in adults and adolescents" Prescrire Int 2025; 34 (268): 67-68. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Baricitinib (Olumiant°)
in severe alopecia areata
in adults"
Prescrire Int 2025;
34 (266): 13-14.
Subscribers only